This e-course will guide you through the essentials of latest existing WHO guidelines and policy recommendations on drug-resistant TB. You will also learn more about the rationale behind the WHO recommendations for the management of DR-TB, implementation considerations for different regimens for eligible patient groups, adjunctive treatment, the active TB drug safety monitoring and management framework, and the analysis and interpretation of performance indicators.
The main focus of the e-course is programmatic; clinical aspects are only discussed when relevant to specific topics.
This e-learning course was developed by WHO. It is a comprehensive, self-paced online course that follows the content of the WHO operational handbook on tuberculosis. Module 4: drug-resistant tuberculosis treatment.
Course duration: 5 to 6 hours
Certificates: Participants with an 80% score or more on the final assessment can download a Record of Achievement. Participants who receive a Record of Achievement can also download an Open Badge for this course. Click here to learn how.
© World Health Organization 2021. All rights reserved. This e-learning training was developed by the World Health Organization (WHO). It is intended to be used as a self-learning course on latest existing WHO guidelines and policy recommendations on drug-resistant TB. All reasonable precautions have been taken by WHO to verify the information contained in this e-learning training. However, the e-learning training is being distributed without warranty of any kind, either expressed or implied. The responsibility for the interpretation and use of the e-learning training lies with the reader. In no event shall WHO be liable for damages arising from its use. The designations employed and the presentation of the material in this publication do not imply the expression of any opinion whatsoever on the part of WHO concerning the legal status of any country, territory, city or area or of its authorities, or concerning the delimitation of its frontiers or boundaries. Dotted and dashed lines on maps represent approximate border lines for which there may not yet be full agreement. The mention of specific companies or of certain manufacturers’ products does not imply that they are endorsed or recommended by the World Health Organization in preference to others of a similar nature that are not mentioned. Errors and omissions excepted, the names of proprietary products are distinguished by initial capital letters.